Advertisement

Supportive Care in Cancer

, Volume 26, Issue 2, pp 575–583 | Cite as

Cognitive functioning and quality of life following chemotherapy in pre- and peri-menopausal women with breast cancer

  • Jennifer R. Klemp
  • Jamie S. MyersEmail author
  • Carol J. Fabian
  • Bruce F. Kimler
  • Qamar J. Khan
  • Susan M. Sereika
  • Annette L. Stanton
Original Article

Abstract

Purpose

The purpose of the study was to prospectively examine changes in subjective and objective cognitive functions and quality of life (QOL) for pre- and peri-menopausal women receiving chemotherapy for breast cancer and to explore potential predictors of cognitive changes.

Methods

Participants were assessed as follows: prior to chemotherapy (T1), after cycle 3 (T2), within 2–3 weeks of completing adjuvant chemotherapy (T3) (N = 20), and 8+ years later (T4; n = 18). Objective cognitive function was measured with the High Sensitivity Cognitive Screen (T1, T3, T4). Subjective measures for cognitive function, depressive symptoms, fatigue, and mental and physical QOL were assessed at all time points. Estradiol levels were measured at T1, T2, and T3. The Functional Assessment of Cancer Therapy-Cognition and the MD Anderson Cancer Symptom Inventory item for neuropathy were administered at T4.

Results

No significant changes in objective cognitive function were found. However, participants reported decreased cognitive function over the course of treatment accompanied by depressive symptoms and fatigue. Depression and fatigue returned to near-baseline levels at T4, but over half of the participants continued to report mild to moderate depression. Estradiol levels were not associated with cognitive function. Neuropathy and higher body mass index (BMI) were associated with persistent cognitive complaints at T4 (adjusted R 2 = 0.712, p = 0.001). Higher QOL was correlated with better subjective cognitive function (r = 0.705, p = 0.002) and lower body mass index (r = − 0.502, p = 0.017) at T4.

Conclusions

Further investigation of BMI, neuropathy, and depressive symptoms as predictors of persistent cognitive dysfunction following chemotherapy for breast cancer is warranted.

Keywords

Breast cancer Cognitive function Pre-menopausal Chemotherapy Quality of life 

Notes

Acknowledgements

This research and Dr. Klemp’s efforts were supported in part by the Department of Defense Breast Cancer Research Program Pre-Doctoral Fellowship: DAMD-17-03-1-0670 and Amgen Inc. A portion of Dr. Myers’ efforts were supported by the National Institution of Nursing Research (NINR) T32 and Interdisciplinary Training of Nurse Scientists in Cancer Survivorship while being a Postdoctoral Scholar at the University of Pittsburgh School of Nursing. The University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Facility Core was supported by the NIH Grant U54-HD28934.

Compliance with ethical standards

Institutional Review Board (IRB) approvals were obtained. All procedures performed in this study were in accordance with the ethical standards of the institutions and were performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained prior to any data collection from all individual participants included in the study.

References

  1. 1.
    Bender CM, Ergun FS, Rosenzweitg MQ, Cohen SM, Sereika SM (2005) Symptom clusters in breast cancer across 3 phases of the disease. Cancer Nurs 28(3):219–225CrossRefPubMedGoogle Scholar
  2. 2.
    Boykoff N, Moleni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3:223–232CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, Hussin MG, Jacobsen PB, Small BJ (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30:3578–3587CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE (2003) Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 9:967–982CrossRefPubMedGoogle Scholar
  5. 5.
    Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J (2005) A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104:2222–2233CrossRefPubMedGoogle Scholar
  6. 6.
    Vardy J, Wefel JS, Ahles TA, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Annals of Oncology: official journal of the European Society for Medical Oncology/ESMO 19(4):623–629CrossRefGoogle Scholar
  7. 7.
    Wefel J, Vardy J, Ahles TA, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. The Lancet Oncology 12:703–708CrossRefPubMedGoogle Scholar
  8. 8.
    Hutchinson A, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38:926–934CrossRefPubMedGoogle Scholar
  9. 9.
    Dumas J (2013) Lifetime hormone exposure and cognition in postmenopausal women with breast cancer. Menopause 20:883–885CrossRefPubMedGoogle Scholar
  10. 10.
    Ryan J, Scali J, Carriere I, Amieva H, Rouaud O, Berr C, Ritchie K (2014) Impact of a premature menopause on cognitive function in later life. Br J Obstet Gynaecol 121:1729–1739CrossRefGoogle Scholar
  11. 11.
    Vearncombe KJ, Pachana NA (2009) Is cognitive functioning detrimentally affected after early, induced menopause? Menopause 16:188–198CrossRefPubMedGoogle Scholar
  12. 12.
    Rey D, Bouhnik AD, Mancini J, Bendiane MK, Seror V, Viens P (2012) Self-reported cognitive impairment after breast cancer treatment in young women from the ELIPPSE40 cohort: the long-term impact of chemotherapy. Breast J 18(5):406–414.  https://doi.org/10.1111/j.1524-4741.2012.01275.x CrossRefPubMedGoogle Scholar
  13. 13.
    Myers JS, Wick J, Klemp JR (2015) Potential factors associated with perceived cognitive impairment in breast cancer survivors. Support Care Cancer 23:3219–3228.  https://doi.org/10.1007/s00520-015-2708-7 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:4175–4183CrossRefGoogle Scholar
  15. 15.
    Faust D, Fogel BS (1989) The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis 177:25–31CrossRefPubMedGoogle Scholar
  16. 16.
    Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21(22):4175–4183CrossRefPubMedGoogle Scholar
  17. 17.
    Derouesne C, Dealberto MJ, Boyer P, Lubin S, Sauron B, Piette F, Kohler F, Alperovitch A (1993) Empirical evaluation of the ‘Cognitive Difficulties Scale’ for assessment of memory complaints in general practice: a study of 1628 cognitively normal subjects aged 45–75 years. Int J Geriatr Psychiatry 8:599–607CrossRefGoogle Scholar
  18. 18.
    Spitznagel MB, Tremont G, Brown LB, Gunstad J (2006) Cognitive reserve and the relationship between depressive symptoms and awareness of deficits in dementia. J Neuropsychiatry Clin Neurosci 18:186–190CrossRefPubMedGoogle Scholar
  19. 19.
    Stanton AL, Bernaards CA, Ganz PA (2005) The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst 97:448–456CrossRefPubMedGoogle Scholar
  20. 20.
    Wagner L, Sweet J, Butt Z, Lai J, Cella D (2009) Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol 7:W32–W39Google Scholar
  21. 21.
    Ware J, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). Med Care 30:473–483CrossRefPubMedGoogle Scholar
  22. 22.
    Ware J, Snow K, Kosinski M, Gandek B (1993) SF-36 health survey: manual and interpretation guide. New England Medical Center, Boston, The Health InstituteGoogle Scholar
  23. 23.
    Ware JH (1994) Physical and mental health summary scales: a user’s manual, 2nd edn. New England Medical Center, Boston, The Health InstituteGoogle Scholar
  24. 24.
    Hays RD, Sherbourne CD, Mazel RM (1993) The RAND 36-item health survey 1.0. Health Econ 2:217–227CrossRefPubMedGoogle Scholar
  25. 25.
    Beck A, Steer R, Garbin M (1988) Psychometric properties of the Beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev 8:77–100CrossRefGoogle Scholar
  26. 26.
    Beck A, Ward C, Mendelson M, Mock J, Eraugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571CrossRefPubMedGoogle Scholar
  27. 27.
    Radloff L (1977) The CES-D scale: a self-reported depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRefGoogle Scholar
  28. 28.
    Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients. Cancer 85:1186–1196CrossRefPubMedGoogle Scholar
  29. 29.
    Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC (2000) Assessing symptom distress in cancer patients: the M.D. Anderson symptom inventory. Cancer 89:1634–1646CrossRefPubMedGoogle Scholar
  30. 30.
    Shi Q, Trask PC, Wang XS, Mendoza TR, Apraku QA, Malekifar M, Cleeland C (2010) Does recall period have an effect on cancer patients’ ratings of the severity of multiple symptoms? J Pain Symptom Manag 40:191–199CrossRefGoogle Scholar
  31. 31.
    BMI Classification. Global database on body mass index. (2015) World Health Organization http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed December 10, 2015
  32. 32.
    Sanford SD, Beaumont JL, Butt Z, Sweet J, Cella D, Wagner L (2014) Prospective longitudinal evaluation of a symptom cluster in breast cancer. J Pain Symptom Manag 47:721–730CrossRefGoogle Scholar
  33. 33.
    Vardy J, Wong K, Yi QL, Park A, Maruff P, Wagner L, Tannock IF (2006) Assessing cognitive function in cancer patients. Support care cancer 14:1111–1118CrossRefPubMedGoogle Scholar
  34. 34.
    Wefel J, A.K. S, Buzdar AU, Meyers C (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348–3356. doi: https://doi.org/10.1002/cncr.25098
  35. 35.
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized longitudinal trial. Cancer 100:2292–2299CrossRefPubMedGoogle Scholar
  36. 36.
    Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, Munzel K (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109:1905–1913CrossRefPubMedGoogle Scholar
  37. 37.
    Poppelreuter M, Weis J, Kutz AK, Tucha O, Lange KW, Bartsch HH (2004) Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 40:43–49CrossRefPubMedGoogle Scholar
  38. 38.
    Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650CrossRefPubMedGoogle Scholar
  39. 39.
    Correa DD, Hess LM (2012) Cognitive function and quality of life in ovarian cancer. Gynecol Oncol 124:404–409CrossRefPubMedGoogle Scholar
  40. 40.
    Pullens MJ, De Vries J, Roukema JA (2010) Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology 19:1127–1138CrossRefPubMedGoogle Scholar
  41. 41.
    Cimprich B, So H, Ronis DL, Trask C (2005) Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology 14:70–78CrossRefPubMedGoogle Scholar
  42. 42.
    Merriman JD, Von Ah D, Miaskowski C, Aouizerat BE (2013) Proposed mechanisms for cancer- and treatment-related cognitive changes. Semin Oncol Nurs 29:260–239CrossRefPubMedGoogle Scholar
  43. 43.
    Li J, Yu L, Long Z, Li Y, Cao F (2014) Perceived cognitive impairment in Chinese patients with breast cancer and its relationship with post-traumatic stress disorder symptoms and fatigue. Psychooncology ePub ahead of print.  https://doi.org/10.1002/pon.3710
  44. 44.
    Myers JS (2012) Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum 39:E31–E40.  https://doi.org/10.1188/12.OONF.E31-E40 CrossRefPubMedGoogle Scholar
  45. 45.
    Mols F, Beijers AJ, Vreugdenhil G, Verhulst A, Schep G, Husson O (2015) Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv 9:512–522CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Jennifer R. Klemp
    • 1
  • Jamie S. Myers
    • 2
    • 4
    Email author
  • Carol J. Fabian
    • 1
  • Bruce F. Kimler
    • 3
  • Qamar J. Khan
    • 1
  • Susan M. Sereika
    • 4
  • Annette L. Stanton
    • 5
  1. 1.University of Kansas Cancer CenterWestwoodUSA
  2. 2.University of Kansas School of NursingKansas CityUSA
  3. 3.University of Kansas Medical CenterKansas CityUSA
  4. 4.School of NursingUniversity of PittsburghPittsburghUSA
  5. 5.Department of PsychologyUniversity of CaliforniaLos AngelesUSA

Personalised recommendations